799b90b715
Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base.
6.1 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | processed_by | processed_date | enrichments_applied | extraction_model | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | Trends in Patient Access to and Utilization of Prescribed PCSK9 Inhibitors in a Large US Claims Database From 2015 to 2021 | Circulation: Cardiovascular Quality and Outcomes (AHA Journals) | https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.123.009988 | 2024-01-01 | health | research-paper | enrichment | high |
|
vida | 2026-03-29 |
|
anthropic/claude-sonnet-4.5 |
Content
Published in Circulation: Cardiovascular Quality and Outcomes, 2024. Large US claims database analysis covering PCSK9 inhibitor prescribing trends 2015–2021.
Key findings:
- Overall penetration: Only 0.9% of ASCVD patients on statin/PCSK9 therapy filled a PCSK9 inhibitor prescription (126,419 patients in sample).
- Time trend: Rose from 0.05% in Q3 2015 to only 2.5% by Q2 2019 — four years after FDA approval, still less than 3% of eligible patients prescribed.
- Initial paid prescription rate: 49.93% — only half of all PCSK9 prescriptions written were successfully filled (compared to 68–84% for other branded cardiometabolic therapies like liraglutide and apixaban).
- Hospitalized ASCVD patients (2020–2022): Only 1.3% received PCSK9 inhibitors despite hospitalization providing an ideal prescribing opportunity.
- The 2018 price reduction (from ~$14,000/year to ~$5,800/year) improved adherence in commercially insured patients but did NOT produce population-level penetration.
Supporting data from companion studies:
- Amgen press release (2017): 83% of PCSK9 prescription claims initially rejected; 57% ultimately rejected — among the highest rejection rates of any cardiovascular drug class.
- Commercial insurance final rejection: 69.5%; Medicare: 42.3% — payer barriers not clinical barriers.
- JAHA 2021 (Adoption study): Sociodemographic disparities — Black and Hispanic ASCVD patients had lower PCSK9 utilization than white patients at all income levels.
Context: PCSK9 inhibitors achieved 15% MACE reduction in FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials on top of statin therapy. They are NOT experimental — they have FDA approval, ACC/AHA guideline endorsement, and proven efficacy. The 1–2.5% population penetration is a price-and-access failure, not an efficacy failure.
Agent Notes
Why this matters: This is the quantitative evidence for the "access-mediated pharmacological ceiling" hypothesis developed in Sessions 10–13. The claim that PCSK9 inhibitors achieve individual efficacy (15% MACE reduction) but fail to reach populations (1–2.5% penetration) is directly supported. This confirms the pharmacological ceiling is NOT a drug-class limitation — it is a pricing and access limitation masquerading as a biological one. What surprised me: The numbers are even lower than the "<5% penetration" estimate used in Session 13. The actual figure is 1–2.5% of eligible ASCVD patients over 4 years post-approval. This makes the access-mediated ceiling argument stronger, not weaker. What I expected but didn't find: Evidence that PCSK9 penetration significantly improved after the 2018 price reduction. The 2018 price cut helped adherence (patients who were prescribed it stayed on it) but did not drive broad population prescribing. KB connections: Directly supports the Session 13 claim candidate: "US cardiovascular mortality stalled after 2010 because next-generation pharmacological interventions (PCSK9 inhibitors, GLP-1 agonists) that show 15–20% individual MACE reductions failed to achieve population-level penetration due to pricing barriers." Also connects to GLP-1 access claims (Medicaid prior auth, India generic vs. US $1,300+/month). Extraction hints:
- "PCSK9 inhibitors achieved only 1–2.5% penetration among eligible ASCVD patients 2015–2019 despite proven 15% MACE reduction in RCTs — direct evidence that the pharmacological ceiling is access-mediated, not drug-class-limited."
- "50% of PCSK9 prescriptions written were never filled due to payer rejection — the highest barrier rate of any major cardiovascular drug class, compared to 16–32% rejection for comparable therapies." Context: Search confirmed from multiple sources: PMC/CVQO trends study, JAHA adoption study, Amgen press release data. The pattern is consistent across data sources and time periods.
Curator Notes
PRIMARY CONNECTION: Session 13 claim candidate: access-mediated pharmacological ceiling; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly.
Key Facts
- PCSK9 inhibitors achieved 15% MACE reduction in FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials
- PCSK9 inhibitor price reduced from ~$14,000/year to ~$5,800/year in 2018
- Only 0.9% of ASCVD patients on statin/PCSK9 therapy filled a PCSK9 inhibitor prescription (126,419 patients in sample)
- PCSK9 penetration rose from 0.05% in Q3 2015 to 2.5% by Q2 2019
- 49.93% of PCSK9 prescriptions written were successfully filled (vs 68-84% for other branded cardiometabolic therapies)
- Only 1.3% of hospitalized ASCVD patients (2020-2022) received PCSK9 inhibitors
- 83% of PCSK9 prescription claims initially rejected; 57% ultimately rejected (Amgen 2017)
- Commercial insurance final rejection: 69.5%; Medicare: 42.3%